Kedrion Biophar Patent-Cliff Exposure & CMS Drug Spending Portfolio
Kedrion Biophar (US): 8 reconciled FDA prescription therapies, $316.9M 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 8 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $316.9M |
| 2024 Medicare Part D Spend | $270.1M |
| 2024 Medicaid Spend | $46.8M |
| California HCAI SB 17 Filings | 18 WAC filings (max 371.1% 2-yr change) |